Drug Profile
DI B4
Alternative Names: Anti-CD19 monoclonal antibody - Merck KGaA; DI-B4Latest Information Update: 19 Oct 2023
Price :
$50
*
At a glance
- Originator Merck KGaA
- Developer Cancer Research Technology; Cancer Research UK
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD19 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I B-cell lymphoma; Chronic lymphocytic leukaemia
Most Recent Events
- 19 Oct 2023 DI B4 is still in phase I trials (Cancer Research UK pipeline, October 2023)
- 28 Sep 2022 No recent reports of development identified for phase-I development in B-cell lymphoma(Late-stage disease, Second-line therapy or greater) in United Kingdom (IV, Infusion)
- 28 Sep 2022 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Late-stage disease, Second-line therapy or greater) in United Kingdom (IV, Infusion)